Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  7/20/2016
Children's Hospital of Alabama
mi
from
Birmingham, AL
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Children's Hospital of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  7/20/2016
Children's Hospital of Orange County
mi
from
Orange, CA
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  7/20/2016
Childrens National Medical Center
mi
from
Washington,
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  7/20/2016
Riley Hospital for Children
mi
from
Indianapolis, IN
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Riley Hospital for Children
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  7/20/2016
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  7/20/2016
Washington University School of Medicine
mi
from
Saint Louis, MO
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  7/20/2016
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  7/20/2016
Oregon Health and Science University
mi
from
Portland, OR
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  7/20/2016
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  7/20/2016
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  7/20/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  7/20/2016
Seattle Children's Hospital
mi
from
Seattle, WA
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  7/20/2016
University of Alabama at Birmingham Cancer Center
mi
from
Birmingham, AL
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
University of Alabama at Birmingham Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  7/20/2016
UCSF Medical Center at Parnassus
mi
from
San Francisco, CA
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
UCSF Medical Center at Parnassus
mi
from
San Francisco, CA
Click here to add this to my saved trials
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  7/20/2016
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Click here to add this to my saved trials
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  7/20/2016
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  7/20/2016
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  7/20/2016
Columbia University Herbert Irving Cancer Center
mi
from
New York, NY
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Columbia University Herbert Irving Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  7/20/2016
Children's Oncology Group
mi
from
Philadelphia, PA
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Children's Oncology Group
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  7/20/2016
Hospital for Sick Children
mi
from
Toronto,
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Hospital for Sick Children
mi
from
Toronto,
Click here to add this to my saved trials
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  7/20/2016
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
mi
from
Houston, TX
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  7/20/2016
Children¿s Hospital of Wisconsin
mi
from
Milwaukee, WI
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 7/20/2016
Children¿s Hospital of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
CPT-SIOP-2009: Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Patients With Choroid Plexus Tumors
Status: Enrolling
Updated:  7/21/2016
Tufts Medical Center
mi
from
Boston, MA
Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
CPT-SIOP-2009: Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Patients With Choroid Plexus Tumors
Status: Enrolling
Updated: 7/21/2016
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
CPT-SIOP-2009: Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Patients With Choroid Plexus Tumors
Status: Enrolling
Updated:  7/21/2016
The Children's Cancer Hospital at UT M.D. Anderson Cancer Center
mi
from
Houston, TX
Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
CPT-SIOP-2009: Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Patients With Choroid Plexus Tumors
Status: Enrolling
Updated: 7/21/2016
The Children's Cancer Hospital at UT M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
CPT-SIOP-2009: Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Patients With Choroid Plexus Tumors
Status: Enrolling
Updated:  7/21/2016
St. Hedwig Children's Hospital, University of Regensburg (International Study Center)
mi
from
Regensburg,
Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
CPT-SIOP-2009: Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Patients With Choroid Plexus Tumors
Status: Enrolling
Updated: 7/21/2016
St. Hedwig Children's Hospital, University of Regensburg (International Study Center)
mi
from
Regensburg,
Click here to add this to my saved trials
DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma
Comprehensive Molecular Analysis of Tumor Samples Derived From Patients With Diffuse Brainstem Glioma - A Pilot Study
Status: Enrolling
Updated:  7/25/2016
Stanford University Medical Center
mi
from
Palo Alto, CA
DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma
Comprehensive Molecular Analysis of Tumor Samples Derived From Patients With Diffuse Brainstem Glioma - A Pilot Study
Status: Enrolling
Updated: 7/25/2016
Stanford University Medical Center
mi
from
Palo Alto, CA
Click here to add this to my saved trials
DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma
Comprehensive Molecular Analysis of Tumor Samples Derived From Patients With Diffuse Brainstem Glioma - A Pilot Study
Status: Enrolling
Updated:  7/25/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma
Comprehensive Molecular Analysis of Tumor Samples Derived From Patients With Diffuse Brainstem Glioma - A Pilot Study
Status: Enrolling
Updated: 7/25/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma
Comprehensive Molecular Analysis of Tumor Samples Derived From Patients With Diffuse Brainstem Glioma - A Pilot Study
Status: Enrolling
Updated:  7/25/2016
Seattle Children's Hospital
mi
from
Seattle, WA
DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma
Comprehensive Molecular Analysis of Tumor Samples Derived From Patients With Diffuse Brainstem Glioma - A Pilot Study
Status: Enrolling
Updated: 7/25/2016
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Survivin-Positive Malignant Gliomas
Status: Enrolling
Updated:  7/25/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Survivin-Positive Malignant Gliomas
Status: Enrolling
Updated: 7/25/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors
Status: Enrolling
Updated:  7/25/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors
Status: Enrolling
Updated: 7/25/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Electronic Medical Record Review in Monitoring the Effects of Adherence on Myelosuppression and Morbidity in Patients With Newly Diagnosed Brain Tumors Receiving Temozolomide and Radiation Therapy
Evaluation of a Data Driven System for Insuring Timely Monitoring for Brain Tumor Patients for Management of Myelosuppression
Status: Enrolling
Updated:  7/26/2016
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
Electronic Medical Record Review in Monitoring the Effects of Adherence on Myelosuppression and Morbidity in Patients With Newly Diagnosed Brain Tumors Receiving Temozolomide and Radiation Therapy
Evaluation of a Data Driven System for Insuring Timely Monitoring for Brain Tumor Patients for Management of Myelosuppression
Status: Enrolling
Updated: 7/26/2016
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Los Angeles, CA
A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Boston, MA
A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Boston, MA
A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Houston, TX
A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma
Status: Enrolling
Updated:  8/1/2016
Research Site
mi
from
Barcelona,
A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma
Status: Enrolling
Updated: 8/1/2016
Research Site
mi
from
Barcelona,
Click here to add this to my saved trials
Information Presentation Formats
Information Presentation Formats and Pursuit of Diagnostic Information
Status: Enrolling
Updated:  8/1/2016
Carnegie Mellon University
mi
from
Pittsburgh, PA
Information Presentation Formats
Information Presentation Formats and Pursuit of Diagnostic Information
Status: Enrolling
Updated: 8/1/2016
Carnegie Mellon University
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Palchak David MD
mi
from
Pismo Beach, CA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Palchak David MD
mi
from
Pismo Beach, CA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Aurora Presbyterian Hospital
mi
from
Aurora, CO
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Aurora Presbyterian Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Boulder Community Hospital
mi
from
Boulder, CO
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Boulder Community Hospital
mi
from
Boulder, CO
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Boulder Community Hospital
mi
from
Boulder, CO
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Boulder Community Hospital
mi
from
Boulder, CO
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Penrose Cancer Center at Penrose Hospital
mi
from
Colorado Springs, CO
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Penrose Cancer Center at Penrose Hospital
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
St. Anthony Central Hospital
mi
from
Denver, CO
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
St. Anthony Central Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Presbyterian - St. Luke's Medical Center
mi
from
Denver, CO
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Presbyterian - St. Luke's Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Rose Medical Center
mi
from
Denver, CO
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Rose Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Porter Adventist Hospital
mi
from
Denver, CO
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Porter Adventist Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Swedish Medical Center
mi
from
Englewood, CO
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Swedish Medical Center
mi
from
Englewood, CO
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
North Colorado Medical Center
mi
from
Greeley, CO
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
North Colorado Medical Center
mi
from
Greeley, CO
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Sky Ridge Medical Center
mi
from
Lone Tree, CO
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Sky Ridge Medical Center
mi
from
Lone Tree, CO
Click here to add this to my saved trials